CHICAGO–Data from a trial of Johnson & Johnson’s blockbuster prostate cancer drug Zytiga (abiraterone) in asymptomatic or mildly symptomatic chemotherapy-naïve patients was received with widespread enthusiasm at the American Society of Clinical Oncology annual meeting, but they also raise some concerns about trial design and statistics that likely will raise flags at FDA and draw an advisory committee review.
Results from the Cougar-302 trial, which was stopped after an interim analysis showed significant improvement in progression-free survival for the...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?